Biologic therapies incorporating PD-1 blocking antibodies in immunogenic cancers like melanoma have resulted in the extended survival rate of patients in randomized controlled trials20,21, which were dependent mainly on a pre-existing infiltrating population of cytotoxic T cells22. The gene discussed is PDCD1; the disease is melanoma.